Breaking News Instant updates and real-time market news.

2021-12-06 10:02:01 DWAC Digital World Acquisition $45.27 / +0.49 (+1.09%) 10:02 12/06/21 12/06 10:02 12/06/21 10:02	Digital World reports receipt of 'fact-finding inquiries' from regulators In a regulatory filing, Digital World Acquisition (DWAC) announced the company has received "certain preliminary, fact-finding inquiries from regulatory authorities," with which it says it is cooperating. "Specifically, in late October and in early November 2021, DWAC received a request for information from FINRA, surrounding events (specifically, a review of trading) that preceded the public announcement of the October 20, 2021 Merger Agreement. According to FINRA's request, the inquiry should not be construed as an indication that FINRA has determined that any violations of Nasdaq rules or federal securities laws have occurred, nor as a reflection upon the merits of the securities involved or upon any person who effected transactions in such securities. Additionally, in early November 2021, DWAC received a voluntary information and document request from the SEC which sought, inter alia, documents relating to meetings of DWAC's Board of Directors, policies and procedures relating to trading, the identification of banking, telephone, and email addresses, the identities of certain investors, and certain documents and communications between DWAC and TMTG. According to the SEC's request, the investigation does not mean that the SEC has concluded that anyone violated the law or that the SEC has a negative opinion of DWAC or any person, event, or security," the filing stated.

2021-12-06 10:02:01

DWAC

Digital World Acquisition

$45.27 / +0.49 (+1.09%)

10:02

12/06/21

12/06

10:02

12/06/21

10:02

Digital World reports receipt of 'fact-finding inquiries' from regulators

In a regulatory filing, Digital World Acquisition (DWAC) announced the company has received "certain preliminary, fact-finding inquiries from regulatory authorities," with which it says it is cooperating. "Specifically, in late October and in early November 2021, DWAC received a request for information from FINRA, surrounding events (specifically, a review of trading) that preceded the public announcement of the October 20, 2021 Merger Agreement. According to FINRA's request, the inquiry should not be construed as an indication that FINRA has determined that any violations of Nasdaq rules or federal securities laws have occurred, nor as a reflection upon the merits of the securities involved or upon any person who effected transactions in such securities. Additionally, in early November 2021, DWAC received a voluntary information and document request from the SEC which sought, inter alia, documents relating to meetings of DWAC's Board of Directors, policies and procedures relating to trading, the identification of banking, telephone, and email addresses, the identities of certain investors, and certain documents and communications between DWAC and TMTG. According to the SEC's request, the investigation does not mean that the SEC has concluded that anyone violated the law or that the SEC has a negative opinion of DWAC or any person, event, or security," the filing stated.

OTHER BREAKING NEWS FROM THE FLY

Conference/Events	American Society of Clinical Oncology (ASCO) to hold a symposium » 04:55 01/22/22 01/22 04:55 01/22/22 04:55 AGEN Agenus $2.70 / -0.055 (-2.00%) , AZN AstraZeneca $59.10 / -1.1 (-1.83%) , BAYRY Bayer $14.62 / -0.26 (-1.75%) , BMY Bristol-Myers $63.56 / -1.045 (-1.62%) , CRDF Cardiff Oncology $3.70 / -0.18 (-4.65%) , DSNKY Daiichi Sankyo $22.66 / -0.03 (-0.13%) , DCPH Deciphera $8.05 / -0.1 (-1.23%) , DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) , ESALY Eisai $51.92 / -0.78 (-1.48%) , EXAS Exact Sciences $74.06 / -2.005 (-2.64%) , EXEL Exelixis $17.34 / +0.29 (+1.70%) , GH Guardant Health $70.17 / -2.36 (-3.25%) , HCM Hutchmed $28.82 / -1.16 (-3.87%) , IMMVF Immunovia $7.40 / + (+0.00%) , INCY Incyte $74.77 / -0.05 (-0.07%) , IPSEY Ipsen $23.66 / +0.38 (+1.63%) , LLY Eli Lilly $243.12 / -0.01 (-0.00%) , MRK Merck $79.98 / -0.765 (-0.95%) , MRTX Mirati Therapeutics $114.10 / -4.4 (-3.71%) , NTRA Natera $62.74 / -0.355 (-0.56%) , NVCR Novocure $67.14 / -2.9 (-4.14%) , NVS Novartis $87.01 / -1.18 (-1.34%) , ORIC Oric Pharmaceuticals $10.96 / -0.37 (-3.27%) , PBLA Panbela Therapeutics $1.60 / -0.09 (-5.33%) , PFE Pfizer $52.78 / -1.3 (-2.40%) , SGEN Seagen $127.66 / -4.85 (-3.66%) , TPTX Turning Point Therapeutics $35.95 / +0.07 (+0.20%) , VCYT Veracyte $27.00 / -0.69 (-2.49%) , ZYME Zymeworks $11.20 / -0.38 (-3.28%) ASCO Gastrointestinal… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZYME VCYT TPTX SGEN PFE PBLA ORIC NVS NVCR NTRA MRTX MRK LLY IPSEY INCY HCM GH EXEL EXAS ESALY DSNKY DNA DCPH CRDF BMY BAYRY AZN AGEN ZYME Zymeworks $11.20 / -0.38 (-3.28%) 01/20/22 Zymeworks falls -6.2% 01/19/22 Zymeworks outlines strategic priorities for 2022 and 2023; reduces workforce 01/12/22 Zymeworks Chief Medical Officer buys 5K shares of common stock VCYT Veracyte $27.00 / -0.69 (-2.49%) 12/14/21 Veracyte announces data demonstrating clinical utility of Envisia 11/24/21 Veracyte receives Swedish MTP Council recommendation for Prosigna reimbursement 10/25/21 Veracyte: Data validate prognostic value of Deciper Prostate genomic test 10/13/21 Veracyte bladder test has ability to identify tumors that will respond to chemo TPTX Turning Point Therapeutics $35.95 / +0.07 (+0.20%) 01/20/22 Turning Point announces FDA clearance of IND for elzovantinib/aumolertinib 01/18/22 Turning Point Therapeutics provides updates, anticipated 2022 milestones 01/18/22 Turning Point Therapeutics expects cash to fund operations into H2 of 2024 12/20/21 Turning Point provides regulatory updates on repotrectinib, TPX-0022 SGEN Seagen $127.66 / -4.85 (-3.66%) 01/18/22 Seagen announces data from SEA-CD40 combination trial at ASCO GI 12/17/21 Seagen's treatment of multiple myeloma receives FDA orphan designation 12/17/21 Astellas Pharma, Seagen announce CHMP opinion recommending approval for Padcev 12/17/21 Astellas Pharma, Seagen receive positive CHMP opinion for PADCEV PFE Pfizer $52.78 / -1.3 (-2.40%) 01/20/22 Japan's MHLW approves Pfizer, OPKO Health's NGENLA 01/19/22 Pfizer awarded $2.05B Army contract modification for more COVID-19 vaccine doses 01/19/22 Sangamo COO sees three 'important catalysts' over next 12 months PBLA Panbela Therapeutics $1.60 / -0.09 (-5.33%) 12/14/21 Panbela Therapeutics announces preclinical data on SBP-101 08/11/21 Panbela Therapeutics provides information on upcoming milestones 08/09/21 Panbela Therapeutics announces issuance of US patent for production of SBP-101 ORIC Oric Pharmaceuticals $10.96 / -0.37 (-3.27%) 01/10/22 Oric Pharmaceuticals expects cash to fund operations into first half of 2024 01/10/22 Oric Pharmaceuticals provides update, key upcoming milestones 12/13/21 Oric Pharmaceuticals presents preclinical CD73 data at ASH 11/04/21 Oric Pharmaceuticals to present update on CD73 Inhibitor Progam NVS Novartis $87.01 / -1.18 (-1.34%) 01/20/22 Bausch Health: Dr. Yehia Hashad to join Bausch + Lomb as Chief Medical Officer 01/19/22 Sangamo CEO says partnerships bring validation to company's technology 01/19/22 Sangamo CEO says preclinical studies moving forward 'beautifully' 01/18/22 Molecular Partners, Novartis enter ensovibep license agreement NVCR Novocure $67.14 / -2.9 (-4.14%) 12/07/21 Novocure to acquire and construct building in Portsmouth, NH 11/29/21 Novocure CEO Danziger buys $510K in company shares 11/22/21 Novocure says last patient enrolled in Lunar trial of TTFields in NSCLC 11/15/21 Novocure reports updated data from 2-THE-TOP trial NTRA Natera $62.74 / -0.355 (-0.56%) 11/19/21 Natera's Panorama SMART study results accepted for publication by AJOG 11/11/21 Medicare expands coverage of Natera's Signatera beyond initial indication 10/11/21 Natera announces new publication validating Signatera MRD test 09/09/21 Natera launches Prospera with Quantification, a cfDNA test MRTX Mirati Therapeutics $114.10 / -4.4 (-3.71%) 01/21/22 Mirati Therapeutics presents results from Phase 2 cohort of KRYSTAL-1 study 12/15/21 Surface Oncology appoints Torres as chair of board of directors 11/22/21 Mirati Therapeutics and Verastem announces collaboration agreement 11/17/21 Mirati Therapeutics submits IND application to FDA for MRTX1719 MRK Merck $79.98 / -0.765 (-0.95%) 01/20/22 IFF names Frank Clyburn as CEO, separates Chairman, CEO roles 01/20/22 Merck's EVP and President, Human Health, Frank Clyburn, to leave on Feb. 1 01/18/22 Keytruda improved OS vs. placebo in HCC patients with prior sorafenib treatment LLY Eli Lilly $243.12 / -0.01 (-0.00%) 01/11/22 Eli Lilly drops 2% to $256 after CMS decision on Biogen Alzheimer's drug 01/06/22 Eli Lilly acquires rights to Fusogenix nucleic acid delivery technology 12/23/21 FDA says Lilly, Regeneron monoclonal antibodies ineffective against omicron 12/21/21 Eli Lilly announces ADhere trial met primary, secondary endpoints IPSEY Ipsen $23.66 / +0.38 (+1.63%) 12/17/21 Ipsen, Genfit enter exclusive license agreement for elafibranor 09/20/21 Mirati Therapeutics appoints David Meek as Chief Executive Officer 08/13/21 Ipsen announces withdrawal of palovarotene NDA following FDA discussions 08/02/21 Ipsen, Exicure enter exclusive collaboration agreement to explore SNAs INCY Incyte $74.77 / -0.05 (-0.07%) 12/14/21 Incyte says FDA accepts ruxolitinib cream sNDA for priority review 12/12/21 MorphoSys, Incyte announce additional real-world evidence results from RE-MIND2 12/12/21 Incyte announces data from three ongoing Phase 2 studies evaluating parsaclisib 12/02/21 Merus announces poster presentation on MCLA-145 at ESMO-IO HCM Hutchmed $28.82 / -1.16 (-3.87%) 01/19/22 Hutchmed initiates Phase I trial of HMPL-653 in China 01/09/22 Hutchmed initiates Phase I study of BTK Inhibitor HMPL-760 in China 12/03/21 Hutchmed announces China NRDL to include Elunate, Sulanda 11/23/21 Hutchmed, AstraZeneca initiate SACHI Phase III trial GH Guardant Health $70.17 / -2.36 (-3.25%) 01/07/22 Guardant Health, Foundation Medicine settle digital sequencing litigation 12/17/21 Guardant Health reaches target enrollment in ECLIPSE trial 11/29/21 Bionano Genomics appoints Keith Gligorich as VP operations for Bionano Labs 11/11/21 Guardant Health announces Guardant360 test helps guide cancer treatment EXEL Exelixis $17.34 / +0.29 (+1.70%) 01/06/22 Exelixis to pay Iconic $55M for rights to use TF antibody incorporated in XB002 01/05/22 Exelixis completes enrollment in CONTACT-03 trial 12/15/21 Exelixis initiates dose-escalation stage of STELLAR-002 trial 11/21/21 Exelixis announces detailed results from Phase 3 COSMIC-312 trial EXAS Exact Sciences $74.06 / -2.005 (-2.64%) 01/20/22 Cathie Wood's ARK Investment bought 172.2K shares of Exact Sciences today 01/12/22 Cathie Wood's ARK Investment bought 41.1K shares of Exact Sciences today 01/09/22 Exact Sciences, OncXerna announce licensing agreement 01/09/22 Exact Sciences acquires PreventionGenetics for $190M ESALY Eisai $51.92 / -0.78 (-1.48%) 01/20/22 Merck's Keytruda combination featured in published Phase 3 study in carcinoma 01/05/22 Roivant Sciences enters licensing agreement with Eisai for RVT-2001 01/04/22 Knight Therapeutics announces approval of Lenvima in Colombia 12/27/21 Japanese MHLW approves combination of KEYTRUDA plus LENVIMA DSNKY Daiichi Sankyo $22.66 / -0.03 (-0.13%) 12/28/21 EMA validates Daiichi Sankyo/AstraZeneca's trastuzumab deruxtecan application 12/23/21 Daiichi Sankyo announces FDA granted BTD to HER3-DXd 12/23/21 Daiichi Sankyo announces first patient dosed in DESTINY-Lung04 phase 3 trial 12/09/21 Daiichi Sankyo, AstraZeneca announce data from additional analyses of ENHERTU DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 01/19/22 Ginkgo Bioworks acquires Project Beacon COVID-19 LLC, terms not disclosed 01/10/22 Selecta Biosciences, Ginkgo Bioworks announced collaboration 01/06/22 Cathie Wood's ARK Investment bought 2.12M shares of Ginkgo Bioworks today 01/06/22 Ginkgo Bioworks, Optimvia partner to manufacture biosynthetic heparin DCPH Deciphera $8.05 / -0.1 (-1.23%) 01/11/22 Oryzon appoints Ana Limon as SVP, clinical development, global medical affairs 12/21/21 Deciphera says UK MHRA grants MA for Qinlock or ripretinib to treat GIST 11/30/21 Deciphera Pharmaceuticals trading resumes 11/30/21 Deciphera reports corporate restructuring, discontinuation of rebastinib program CRDF Cardiff Oncology $3.70 / -0.18 (-4.65%) 01/18/22 Cardiff Oncology reports new data from clinical program in KRAS-mutated cancer 01/11/22 Cardiff Oncology names Tod Smeal, Ph.D., as Chief Scientific Officer 11/18/21 Cardiff Oncology announces $15M equity investment from Pfizer 09/13/21 Cardiff Oncology CFO buys 30K share of common stock BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 01/21/22 Rafael announces William Conkling to assume role of CEO 01/20/22 Bristol-Myers announces approval for Abecma in Japan 01/11/22 Evogene announces clearance for Phase I clinical trial of BMC-128 in Israel 01/10/22 BioAtla, Bristol-Myers announce clinical collaboration BAYRY Bayer $14.62 / -0.26 (-1.75%) 12/06/21 Recursion Pharmaceuticals, Bayer expand fibrosis collaboration 12/01/21 Point Biopharma announces changes to leadership team, appoints Kelly as COO 11/09/21 Bayer continues to expect FY sales EUR 43B 09/20/21 Bayer extends KERENDIA development with study in use as CKD treatment AZN AstraZeneca $59.10 / -1.1 (-1.83%) 01/18/22 AstraZeneca's TOPAZ-1 trial of Imfinzi shows reduced risk of death in BTC 01/18/22 AstraZeneca announces reduced risk of death from tremelimumab+Imfinzi 01/17/22 Enhertu granted priority review in HER2-positive metastatic breast cancer 01/13/22 Amgen, AstraZeneca: Tezspire now available for shipment in U.S. AGEN Agenus $2.70 / -0.055 (-2.00%) 12/22/21 Agenus announces Bal plus Zal data published in JCO 11/12/21 Agenus presents clincial data for AGEN1181 11/09/21 Agenus reports Q3 EPS 72c, three estimates 46c 10/22/21 Agenus withdraws BLA for balstilimab, decides to discontinue BRAVA trial AGEN AZN BAYRY BMY CRDF DSNKY DCPH DNA ESALY EXAS EXEL GH HCM IMMVF INCY IPSEY LLY MRK MRTX NTRA NVCR NVS ORIC PBLA PFE SGEN TPTX VCYT ZYME AGEN Agenus $2.70 / -0.055 (-2.00%) 12/16/21 H.C. Wainwright Agenus initiated with a Buy at H.C. Wainwright 12/06/21 B. Riley B. Riley bullish on Novavax, Agenus amid Omicron spread 11/09/21 Evercore ISI Evercore starts Agenus spinout MiNK Therapeutics with an Outperform 10/25/21 B. Riley Agenus price target lowered to $11 from $12 at B. Riley AZN AstraZeneca $59.10 / -1.1 (-1.83%) 12/30/21 SVB Leerink SVB Leerink confident Adbry poses minimal competitive risk to Dupixent 12/16/21 Morgan Stanley AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley 12/16/21 Stifel Adagio story 'even more complicated' after preprints on ADG20, says Stifel 12/12/21 Piper Sandler Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper BAYRY Bayer $14.62 / -0.26 (-1.75%) 11/15/21 AlphaValue/Baader Bayer upgraded to Buy from Add at AlphaValue/Baader 11/10/21 JPMorgan Bayer price target raised to EUR 75 from EUR 67 at JPMorgan 11/10/21 Morgan Stanley Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley 11/10/21 Credit Suisse Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 01/10/22 Piper Sandler Piper says Century Therapeutics' alliance with Bristol 'transformational' 01/03/22 Piper Sandler Legend Biotech named a top pick for 2022 at Piper Sandler 12/21/21 Oppenheimer Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential 12/21/21 Piper Sandler Legend Biotech initiated with an Overweight at Piper Sandler CRDF Cardiff Oncology $3.70 / -0.18 (-4.65%) 12/07/21 Baird Cardiff Oncology initiated with an Outperform at Baird 11/18/21 Piper Sandler Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler 09/09/21 Maxim Cardiff Oncology price target raised to $25 from $20 at Maxim 09/09/21 Piper Sandler Cardiff colorectal cancer data 'very consistent,' says Piper Sandler DSNKY Daiichi Sankyo $22.66 / -0.03 (-0.13%) 10/27/21 SVB Leerink Seagen price target raised to $200 from $190 at SVB Leerink 03/15/21 Citi Citi opens 'positive catalyst watch' on Daiichi Sankyo 03/08/21 Goldman Sachs Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs DCPH Deciphera $8.05 / -0.1 (-1.23%) 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss 11/08/21 Canaccord Deciphera downgraded to Hold at Canaccord DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 01/06/22 BTIG BTIG starts Ginkgo Bioworks at Buy with $12 price target 01/06/22 BTIG Ginkgo Bioworks initiated with a Buy at BTIG 11/29/21 Jefferies Ginkgo Bioworks initiated with a Buy at Jefferies 10/20/21 Raymond James Raymond James expects more equity-based payments for Ginkgo as milestones met ESALY Eisai $51.92 / -0.78 (-1.48%) 01/13/22 Citi Eisai downgraded to Neutral from Buy at Citi 10/08/21 Jefferies Biogen price target lowered to $400 from $500 at Jefferies 09/30/21 RBC Capital Prothena price target raised to $82 from $59 at RBC Capital 06/25/21 Morgan Stanley Eisai downgraded to Equal Weight from Overweight at Morgan Stanley EXAS Exact Sciences $74.06 / -2.005 (-2.64%) 11/03/21 BTIG Exact Sciences price target lowered to $120 from $145 at BTIG 11/03/21 Craig-Hallum Exact Sciences price target lowered to $133 from $144 at Craig-Hallum 11/03/21 Raymond James Exact Sciences downgraded to Outperform from Strong Buy at Raymond James 11/03/21 Wells Fargo Exact Sciences price target lowered to $95 from $120 at Wells Fargo EXEL Exelixis $17.34 / +0.29 (+1.70%) 11/18/21 Piper Sandler Exelixis transferred with Overweight at Piper Sandler 11/03/21 H.C. Wainwright Exelixis price target lowered to $52 from $65 at H.C. Wainwright 10/06/21 Jefferies Exelixis initiated with a Buy at Jefferies 08/06/21 H.C. Wainwright Exelixis price target raised to $64 from $35 at H.C. Wainwright GH Guardant Health $70.17 / -2.36 (-3.25%) 10/14/21 Cowen Guardant Health coverage transferred at Cowen 08/09/21 Canaccord Guardant Health price target lowered to $180 from $195 at Canaccord 06/21/21 Wells Fargo Guardant Health price target raised to $160 from $145 at Wells Fargo 06/15/21 Fly Intel: Top five analyst initiations HCM Hutchmed $28.82 / -1.16 (-3.87%) 09/22/21 Fly Intel: Top five analyst downgrades 09/22/21 Goldman Sachs Hutchmed downgraded to Neutral from Buy at Goldman Sachs 08/03/21 Jefferies Hutchmed initiated with a Buy at Jefferies 07/13/21 Cantor Fitzgerald Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald IMMVF Immunovia $7.40 / + (+0.00%) 12/22/21 Kempen Immunovia downgraded to Neutral from Buy at Kempen INCY Incyte $74.77 / -0.05 (-0.07%) 01/18/22 RBC Capital Incyte upgraded to Outperform at RBC Capital on improving 2022 setup 01/18/22 RBC Capital Incyte upgraded to Outperform from Sector Perform at RBC Capital 01/03/22 Guggenheim Incyte price target lowered to $104 from $118 at Guggenheim 12/31/21 Benchmark Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark IPSEY Ipsen $23.66 / +0.38 (+1.63%) 01/11/22 Bryan Garnier Ipsen upgraded to Buy from Neutral at Bryan Garnier 01/06/22 Societe Generale Ipsen upgraded to Buy from Hold at Societe Generale 01/04/22 JPMorgan Ipsen downgraded to Neutral from Overweight at JPMorgan 11/24/21 Berenberg Ipsen initiated with a Hold at Berenberg LLY Eli Lilly $243.12 / -0.01 (-0.00%) 01/21/22 DZ Bank Eli Lilly upgraded to Buy from Hold at DZ Bank 01/14/22 BofA Biogen price target lowered to $245 from $275 at BofA 01/12/22 Wells Fargo CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo 01/05/22 Mizuho Eli Lilly price target raised to $302 from $272 at Mizuho MRK Merck $79.98 / -0.765 (-0.95%) 12/23/21 Mizuho Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid 12/17/21 Goldman Sachs Goldman starts Merck at Conviction Buy with market undervaluing assets 12/17/21 Goldman Sachs Merck initiated with a Conviction Buy at Goldman Sachs 12/16/21 Daiwa Merck initiated with a Neutral at Daiwa MRTX Mirati Therapeutics $114.10 / -4.4 (-3.71%) 11/18/21 BMO Capital Amgen initiated with a Market Perform at BMO Capital 11/18/21 BMO Capital Mirati Therapeutics initiated with an Outperform at BMO Capital 09/22/21 Stifel Mirati Therapeutics initiated with a Buy at Stifel 09/22/21 Citi Mirati Therapeutics price target raised to $244 from $232 at Citi NTRA Natera $62.74 / -0.355 (-0.56%) 01/12/22 BTIG Natera price target lowered to $150, named one of top 2022 picks at BTIG 01/05/22 Piper Sandler Natera assumed with an Overweight at Piper Sandler 01/04/22 Canaccord Natera weakness a buying opportunity, says Canaccord 11/05/21 Baird Natera price target raised to $152 from $145 at Baird NVCR Novocure $67.14 / -2.9 (-4.14%) 01/20/22 Truist Novocure upgraded to Buy on more favorable risk-reward at Truist 01/20/22 Truist Novocure upgraded to Buy from Hold at Truist 01/11/22 Wells Fargo Novocure price target lowered to $70 from $105 at Wells Fargo 01/10/22 Piper Sandler Novocure price target lowered to $125 from $130 at Piper Sandler NVS Novartis $87.01 / -1.18 (-1.34%) 01/12/22 Alliance Global Partners OpGen price target lowered to $3 from $4.35 at Alliance Global Partners 01/10/22 Citi Novartis resumed with a Buy at Citi 01/06/22 Piper Sandler Piper want to own Alnylam shares ahead of expected vutrisiran approval 12/15/21 Berenberg Novartis price target lowered to CHF 85 from CHF 88 at Berenberg ORIC Oric Pharmaceuticals $10.96 / -0.37 (-3.27%) 10/08/21 Baird Oric Pharmaceuticals price target lowered to $26 from $47 at Baird 10/08/21 Citi Oric Pharmaceuticals price target lowered to $22 from $33 at Citi 10/08/21 H.C. Wainwright Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright 10/07/21 Oppenheimer Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone' PBLA Panbela Therapeutics $1.60 / -0.09 (-5.33%) 06/28/21 Roth Capital Panbela Therapeutics initiated with a Buy at Roth Capital 03/10/21 Maxim Panbela Therapeutics initiated with a Buy at Maxim PFE Pfizer $52.78 / -1.3 (-2.40%) 01/14/22 BMO Capital Pfizer price target raised to $76 from $60 at BMO Capital 01/11/22 BofA Pfizer added to US 1 List; Goldman Sachs removed at BofA 01/10/22 Wedbush Beam Therapeutics price target raised to $159 from $148 at Wedbush 01/05/22 BofA Pfizer upgraded to Buy from Neutral at BofA SGEN Seagen $127.66 / -4.85 (-3.66%) 11/08/21 Wolfe Research Seagen initiated with a Peer Perform at Wolfe Research 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler 10/28/21 Piper Sandler Seagen price target raised to $165 from $160 at Piper Sandler TPTX Turning Point Therapeutics $35.95 / +0.07 (+0.20%) 01/21/22 Oppenheimer Turning Point Therapeutics price target lowered to $105 from $115 at Oppenheimer 01/03/22 Guggenheim Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim 12/22/21 Roth Capital Turning Point FDA feedback appears positive, says Roth Capital 12/06/21 Cowen Turning Point Therapeutics initiated with an Outperform at Cowen VCYT Veracyte $27.00 / -0.69 (-2.49%) 01/06/22 Stephens Veracyte initiated with Overweight, named best idea at Stephens 11/18/21 Goldman Sachs Veracyte reinstated with a Buy at Goldman Sachs 11/10/21 Raymond James Veracyte price target raised to $62 from $50 at Raymond James 06/28/21 Raymond James Veracyte price target raised to $50 from $45 at Raymond James ZYME Zymeworks $11.20 / -0.38 (-3.28%) 12/10/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James 12/10/21 SVB Leerink Zymeworks upgraded to Outperform from Market Perform at SVB Leerink 12/09/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James 11/17/21 Guggenheim Zymeworks assumed with a Neutral at Guggenheim ZYME VCYT TPTX SGEN PFE PBLA ORIC NVS NVCR NTRA MRTX MRK LLY INCY GH EXEL EXAS DNA DCPH CRDF BMY BAYRY AZN AGEN ZYME Zymeworks $11.20 / -0.38 (-3.28%) 11/03/21 Zymeworks reports Q3 EPS ($1.25), consensus ($1.17) 08/04/21 Zymeworks reports Q2 EPS ($1.31), consensus ($1.05) VCYT Veracyte $27.00 / -0.69 (-2.49%) 11/09/21 Veracyte raises FY21 revenue view to $210M-$218M from $200M-$208M 11/09/21 Veracyte reports Q3 EPS (20c), consensus (16c) 07/29/21 Veracyte raises FY21 revenue view to $200M-$208M, consensus $197.9M 07/29/21 Veracyte reports Q2 EPS (13c), consensus (25c) TPTX Turning Point Therapeutics $35.95 / +0.07 (+0.20%) 11/09/21 Turning Point Therapeutics reports Q3 EPS ($1.34), consensus ($1.27) 08/09/21 Turning Point Therapeutics reports Q2 EPS (1.14c), consensus ($1.21) SGEN Seagen $127.66 / -4.85 (-3.66%) 10/28/21 Seagen reports Q3 EPS ($1.61), consensus (57c) 07/29/21 Seagen reports Q2 EPS (47c), consensus (60c) PFE Pfizer $52.78 / -1.3 (-2.40%) 11/02/21 Pfizer raises FY21 adjusted EPS view to $4.13-$4.18 from $3.95-$4.05 11/02/21 Pfizer reports Q3 adjusted EPS $1.34 vs. 59c a year ago 11/01/21 Notable companies reporting before tomorrow's open PBLA Panbela Therapeutics $1.60 / -0.09 (-5.33%) 08/11/21 Panbela Therapeutics reports Q2 EPS (22c), consensus (18c) ORIC Oric Pharmaceuticals $10.96 / -0.37 (-3.27%) 11/08/21 Oric Pharmaceuticals reports Q3 EPS (47c) consensus (58c) NVS Novartis $87.01 / -1.18 (-1.34%) 10/26/21 Novartis reports Q3 core EPS $1.71, consensus $1.65 NVCR Novocure $67.14 / -2.9 (-4.14%) 01/10/22 Novocure reports preliminary Q4 revenue $133.2M, consensus $137.36M 10/28/21 Novocure reports Q3 EPS (13c), consensus (7c) 07/29/21 Novocure reports Q2 EPS (14c), consensus 1c NTRA Natera $62.74 / -0.355 (-0.56%) 11/04/21 Natera sees FY21 revenue $615M-$625M, consensus $614.7M 11/04/21 Natera reports Q3 EPS ($1.63), consensus ($1.27) 08/05/21 Natera raises FY21 revenue view to $600M-$620M from $550M-$575M 08/05/21 Natera reports Q2 EPS ($1.32), consensus ($1.08) MRTX Mirati Therapeutics $114.10 / -4.4 (-3.71%) 11/08/21 Mirati Therapeutics reports Q3 EPS ($1.55), consensus ($2.89) 08/05/21 Mirati Therapeutics reports Q2 EPS ($3.23), consensus ($2.40) MRK Merck $79.98 / -0.765 (-0.95%) 10/28/21 Merck raises FY21 adjusted EPS view to $5.65-$5.70, consensus $5.77 10/28/21 Merck reports Q3 adjusted EPS $1.75, consensus $1.55 10/27/21 Notable companies reporting before tomorrow's open LLY Eli Lilly $243.12 / -0.01 (-0.00%) 12/15/21 Eli Lilly sees FY22 EPS $8.50-$8.65, consensus $7.30 12/15/21 Eli Lilly raises FY21 adjusted EPS view to $8.15-$8.20 from $7.95-$8.05 10/26/21 Eli Lilly raises FY21 adjusted EPS view to $7.95-$8.05 from $7.80-$8.00 INCY Incyte $74.77 / -0.05 (-0.07%) 11/09/21 Eli Lilly and Incyte presents results from Olumiant study 11/02/21 Incyte reports Q3 EPS $1.18, consensus 74c 08/03/21 Incyte reports Q2 EPS 80c, consensus 75c GH Guardant Health $70.17 / -2.36 (-3.25%) 11/04/21 Guardant Health sees FY21 revenue $360M-$370M, consensus $366.7M 11/04/21 Guardant Health reports Q3 EPS ($1.06), consensus (96c) 08/05/21 Guardant Health sees FY21 revenue $360M-$370M, consensus $367.97M 08/05/21 Guardant Health reports Q2 adjusted EPS (61c), consensus (87c) EXEL Exelixis $17.34 / +0.29 (+1.70%) 01/09/22 Exelixis sees preliminary Q4 net product revenue $300M 11/02/21 Exelixis reports Q3 EPS 20c, consensus 16c 08/05/21 Exelixis sees FY21 revenue $1.3B-$1.4B, consensus $1.23B 08/05/21 Exelixis reports Q2 adjusted EPS 37c, consensus 7c EXAS Exact Sciences $74.06 / -2.005 (-2.64%) 01/09/22 Exact Sciences reports preliminary Q4 revenue $472M-$475M, consensus $440.3M 11/02/21 Exact Sciences sees FY21 revenue $1.722B-$1.737B, consensus $1.73B 11/02/21 Exact Sciences reports Q3 EPS (97c), consensus (85c) 07/28/21 Exact Sciences raises FY21 revenue view to $1.705B-$1.745B from $1.69B-$1.735B DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 01/12/22 Ginkgo Bioworks sees 2021 revenue above guidance 11/15/21 Ginkgo Bioworks reports Q3 EPS (8c), two estimates (3c) DCPH Deciphera $8.05 / -0.1 (-1.23%) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) 08/03/21 Deciphera reports Q2 EPS ($1.21), consensus ($1.15) CRDF Cardiff Oncology $3.70 / -0.18 (-4.65%) 11/04/21 Cardiff Oncology reports Q3 EPS (17c), consensus (17c) 08/05/21 Cardiff Oncology reports Q2 EPS (17c), consensus (15c) BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 10/27/21 Acceleron expects Q3 royalty revenue of approximately $32M from Reblozy 10/27/21 Bristol-Myers narrows FY21 non-GAAP EPS view to $7.40-$7.55 from $7.35-$7.55 10/27/21 Bristol-Myers reports Q3 EPS $2.00, consensus $1.92 10/26/21 Notable companies reporting before tomorrow's open BAYRY Bayer $14.62 / -0.26 (-1.75%) 11/09/21 Bayer reports Q3 core EPS EUR 1.05 vs. EUR 0.81 last year 08/05/21 Bayer raises 2021 core EPS view EUR6.00-EUR6.20 from EUR5.60-EUR5.80 08/05/21 Bayer reports Q2 core EPS EUR1.61 vs. EUR1.59 last year AZN AstraZeneca $59.10 / -1.1 (-1.83%) 11/12/21 Compugen reports Q3 EPS (7c), consensus (12c) 11/12/21 AstraZeneca backs FY21 core EPS view of $5.05-$5.40, consensus $3.27 11/12/21 AstraZeneca reports Q3 core EPS $1.08, two estimates 62c 07/29/21 AstraZeneca sees FY21 core EPS $5.05-$5.40, consensus $5.14 AGEN Agenus $2.70 / -0.055 (-2.00%) 08/09/21 Agenus reports Q2 EPS (37c), consensus (24c) 11 Nov 22 Jul 05 Feb ZYME PFE NVS NTRA MRK LLY GH EXAS ESALY DNA BMY BAYRY AZN ZYME Zymeworks $11.20 / -0.38 (-3.28%) 09/17/21 Zymeworks data 'could intensify potential sale talks,' Dealreporter says PFE Pfizer $52.78 / -1.3 (-2.40%) 01/17/22 Study says 4th Pfizer doze insufficient to ward off Omicron, Bloomberg reports 01/15/22 GSK rejected unsolicited GBP 50B bid from Unilever for consumer unit, Times says 01/11/22 Pfizer trimming U.S. salesforce as meetings go virtual, Reuters reports 01/11/22 Pfizer CEO Bourla says 2 vaccine doses aren't 'enough' for omicron, CNBC reports NVS Novartis $87.01 / -1.18 (-1.34%) 12/06/21 Novartis at work on pan-coronavirus oral treatment, Reuters reports 11/22/21 Novartis plans new sales strategy for cholesterol drug launch, WSJ reports 11/19/21 EQT, Struengmann family weigh Sandoz offer, Reuters reports NTRA Natera $62.74 / -0.355 (-0.56%) 01/03/22 NY Times investigation finds 85% of positive results from NIPTs are incorrect MRK Merck $79.98 / -0.765 (-0.95%) 12/22/21 France cancels order for Merck COVID antiviral drug, Reuters reports 12/21/21 FDA could authorize Pfizer, Merck Covid pills this week, Bloomberg reports 11/30/21 FDA panel votes 13-10 in support of Merck COVID pill, CNBC reports LLY Eli Lilly $243.12 / -0.01 (-0.00%) 12/22/21 Most monoclonal antibody treatments failing against omicron, NY Times reports 12/03/21 FDA planning fast review of omicron vaccines and drugs, WSJ reports 11/30/21 COVID-19 antibody drugs struggle with omnicron, WSJ reports 11/30/21 Moderna CEO expects current vaccines to struggle with omicron, FT says GH Guardant Health $70.17 / -2.36 (-3.25%) 10/04/21 Guardant Health opting not to pursue deal to buy NeoGenomics, Bloomberg says 10/01/21 Guardant Health considering possible takeover of NeoGenomics, Bloomberg says 10/01/21 Guardant Health exploring possible deal to buy NeoGenomics, Bloomberg says EXAS Exact Sciences $74.06 / -2.005 (-2.64%) 08/06/21 Exact Sciences approaches Invitae about possible tie-up, Bloomberg reports ESALY Eisai $51.92 / -0.78 (-1.48%) 12/22/21 Japanese panel said difficult to determine efficacy of Adulhelm, Reuters report 08/17/21 Biogen, Eisai drug Aduhelm to be used at over 300 hospitals, Nikkei reports DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 10/06/21 Ginkgo 'very legal' scheme, not 'scam,' Citron Research says 10/06/21 Ginkgo Bioworks called 'colossal scam' in Scorpion Capital short report BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 12/04/21 Bristol stock too cheap, could be ready to rally, Barron's says 11/18/21 J&J expects to file for approval of 14 new drugs by 2025, Reuters reports 11/12/21 Biden to nominate Robert Califf to lead FDA, Politico reports 11/03/21 Democrats reach agreement to lower prescription prices, WSJ reports BAYRY Bayer $14.62 / -0.26 (-1.75%) 11/18/21 Bayer CEO rejects business division breakup, Bloomberg reports 10/08/21 Bayer pest control unit draws interest from several PE suitors, Bloomberg says 08/09/21 Bayer loses third straight Roundup verdict appeal, Bloomberg says 08/09/21 Bayer loses another appeal of Roundup case, Bloomberg says AZN AstraZeneca $59.10 / -1.1 (-1.83%) 12/23/21 Nigeria destroys 1M expired AstraZeneca vaccine doses, Reuters reports 12/22/21 U.S. in talks to buy more of AstraZeneca COVID prevention drug, Bloomberg says 12/03/21 AstraZeneca weighing options for new vaccines division, Bloomberg reports 12/03/21 AstraZeneca weighing options for new vaccines division, Bloomberg reports ZYME VCYT SGEN PFE NVS MRTX MRK LLY IPSEY INCY GH EXEL EXAS DNA DCPH CRDF BMY BAYRY AZN AGEN ZYME Zymeworks $11.20 / -0.38 (-3.28%) 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday VCYT Veracyte $27.00 / -0.69 (-2.49%) 10/11/21 Fly Intel: After-Hours Movers 07/29/21 Fly Intel: After-Hours Movers SGEN Seagen $127.66 / -4.85 (-3.66%) 10/11/21 Starbucks upgrade, DraftKings initiation among today's top calls on Wall Street 10/06/21 Before the Move: Watch Bicycle Therapeutics ahead of new cancer data 09/20/21 Fly Intel: After-Hours Movers PFE Pfizer $52.78 / -1.3 (-2.40%) 01/18/22 Wall Street in Fives - Must Read Lists at Midday 01/13/22 Wall Street in Fives - Must Read Lists for Thursday NVS Novartis $87.01 / -1.18 (-1.34%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung 01/18/22 Fly Intel: Pre-market Movers 12/16/21 Fly Intel: Pre-market Movers MRTX Mirati Therapeutics $114.10 / -4.4 (-3.71%) 11/08/21 Fly Intel: After-Hours Movers MRK Merck $79.98 / -0.765 (-0.95%) 01/07/22 Wall Street in Fives - Must Read Lists for Friday 01/07/22 Wall Street in Fives - Must Read Lists at Midday 12/23/21 Wall Street in Fives - Must Read Lists at Midday LLY Eli Lilly $243.12 / -0.01 (-0.00%) 01/12/22 Biogen slides after proposed narrow coverage from CMS for Alzheimer's drug 12/23/21 Wall Street in Fives - Must Read Lists for Thursday 12/15/21 Wall Street in Fives - Must Read Lists for Wednesday IPSEY Ipsen $23.66 / +0.38 (+1.63%) 12/17/21 Wall Street in Fives - Must Read Lists for Friday 12/17/21 Wall Street in Fives - Must Read Lists at Midday INCY Incyte $74.77 / -0.05 (-0.07%) 12/31/21 Wall Street in Fives - Must Read Lists for Friday 12/31/21 Wall Street in Fives - Must Read Lists at Midday 12/20/21 Fly Insider: Venus Concept, Alpha & Omega among week's notable insider trades 09/22/21 Wall Street in Fives - Must Read Lists for Wednesday GH Guardant Health $70.17 / -2.36 (-3.25%) 10/04/21 Wall Street in Fives - Must Read Lists for Monday 10/04/21 Wall Street in Fives - Must Read Lists at Midday 10/01/21 Wall Street in Fives - Must Read Lists for Friday 10/01/21 Wall Street in Fives - Must Read Lists at Midday EXEL Exelixis $17.34 / +0.29 (+1.70%) 09/20/21 Wall Street in Fives - Must Read Lists at Midday 09/20/21 Fly Intel: Pre-market Movers EXAS Exact Sciences $74.06 / -2.005 (-2.64%) 11/02/21 Fly Intel: After-Hours Movers 07/28/21 Fly Intel: After-Hours Movers DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 01/06/22 Fly Intel: After-Hours Movers 10/06/21 Wall Street in Fives - Must Read Lists for Wednesday 10/06/21 Wall Street in Fives - Must Read Lists at Midday 09/20/21 Wall Street in Fives - Must Read Lists for Monday DCPH Deciphera $8.05 / -0.1 (-1.23%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday CRDF Cardiff Oncology $3.70 / -0.18 (-4.65%) 09/08/21 Fly Intel: After-Hours Movers BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney 01/10/22 Wall Street in Fives - Must Read Lists for Monday 01/10/22 Wall Street in Fives - Must Read Lists at Midday 12/13/21 Wall Street in Fives - Must Read Lists for Monday BAYRY Bayer $14.62 / -0.26 (-1.75%) 10/08/21 Wall Street in Fives - Must Read Lists for Friday 09/27/21 Acceleron up amid report of talks, Cowen says $180 per share 'too low' a price 07/30/21 Wall Street in Fives - Must Read Lists at Midday AZN AstraZeneca $59.10 / -1.1 (-1.83%) 01/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/16/21 Wall Street in Fives - Must Read Lists at Midday 12/03/21 Wall Street in Fives - Must Read Lists for Friday 12/03/21 Wall Street in Fives - Must Read Lists at Midday AGEN Agenus $2.70 / -0.055 (-2.00%) 09/16/21 Fly Intel: After-Hours Movers 01/29/22 58th Annual Meeting of STS 02/02/22 EAHAD 2022 Virtual Congress 02/02/22 Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR 02/17/22 ASCO Genitourinary Cancers Symposium 2022 06/03/22 2022 ASCO Annual Meeting 02/03/22 Merck - MRK 02/03/22 Eli Lilly - LLY 02/04/22 Bristol-Myers - BMY 02/08/22 Incyte - INCY 02/08/22 Pfizer - PFE 02/09/22 Seagen - SGEN 02/24/22 Novocure - NVCR 01/23/22 PDUFA Date for Cabotegravir 01/24/22 PDUFA Date for Somatrogon - Extended 01/28/22 PDUFA Date for Mavacamten 03/19/22 PDUFA Date Relatlimab & Nivolumab 03/21/22 Extended PDUFA Date for Gefapixant 03/27/22 PDUFA Date for Reblozyl 03/28/22 PDUFA Date for KEYTRUDA (Keynote 158 Trial) 04/01/22 PDUFA Date for Vaxneuvance 04/28/22 Extended PDUFA Date for Mavacamten 04/30/22 PDUFA Date for Parsaclisib 05/06/22 PDUFA Date for MYFEMBREE 05/28/22 PDUFA Date for Opdivo (Nivolumab) With Yervoy (Ipilimumab) 05/28/22 Opdivo with Fluoropyrimidine- and platinum-containing chemotherapy 09/10/22 PDUFA Date for Deucravacitinib (POETYK PSO-2) PFE NVS MRK LLY INCY DNA BMY AZN AGEN PFE Pfizer $52.78 / -1.3 (-2.40%) 12/23/21 Notable open interest changes for December 23rd 12/22/21 Unusually active option classes on open December 22nd 12/22/21 Notable open interest changes for December 22nd NVS Novartis $87.01 / -1.18 (-1.34%) 10/04/21 Novartis put volume heavy and directionally bearish MRK Merck $79.98 / -0.765 (-0.95%) 01/05/22 Merck call volume above normal and directionally bullish 12/01/21 Unusually active option classes on open December 1st 11/29/21 Merck call volume above normal and directionally bullish 11/02/21 Merck call volume above normal and directionally bullish LLY Eli Lilly $243.12 / -0.01 (-0.00%) 12/15/21 Early notable gainers among liquid option names on December 15th 11/19/21 Early notable gainers among liquid option names on November 19th 11/17/21 Early notable gainers among liquid option names on November 17th 08/03/21 Early notable gainers among liquid option names on August 3rd INCY Incyte $74.77 / -0.05 (-0.07%) 12/31/21 Early notable gainers among liquid option names on December 31st 11/03/21 Early notable gainers among liquid option names on November 3rd 09/20/21 Early notable gainers among liquid option names on September 20th DNA Ginkgo Bioworks $5.27 / +0.165 (+3.23%) 01/21/22 Ginkgo Bioworks call volume above normal and directionally bullish 01/18/22 Ginkgo Bioworks put volume heavy and directionally bearish 12/29/21 Largest borrow rate increases among liquid names 12/27/21 Largest borrow rate increases among liquid names BMY Bristol-Myers $63.56 / -1.045 (-1.62%) 01/10/22 Early notable gainers among liquid option names on January 10th 12/15/21 Bristol Myers Squibb call volume above normal and directionally bullish 12/13/21 Early notable gainers among liquid option names on December 13th 10/01/21 Bristol Myers Squibb call volume above normal and directionally bullish AZN AstraZeneca $59.10 / -1.1 (-1.83%) 01/05/22 AstraZeneca call volume above normal and directionally bullish 11/16/21 Unusually active option classes on open November 16th 11/12/21 AstraZeneca put volume heavy and directionally bearish 11/12/21 Unusually active option classes on open November 12th AGEN Agenus $2.70 / -0.055 (-2.00%) 11/05/21 Pre-earnings put spread buyer in Agenus
Periodicals	Judge denies McDonald's motion to dismiss Byron Allen's suit, Bloomberg says 18:33 01/21/22 01/21 18:33 01/21/22 18:33 MCD McDonald's $254.64 / +1.52 (+0.60%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MCD McDonald's $254.64 / +1.52 (+0.60%) 12/21/21 MasterCard to acquire McDonald's personalization platform Dynamic Yield 11/10/21 McDonald's announces December collaboration with Mariah Carey 10/27/21 McDonald's says staffing environment 'very challenging' in U.S. 10/27/21 IBM to acquire McD Tech Labs from McDonald's MCD McDonald's $254.64 / +1.52 (+0.60%) 01/21/22 BTIG Beyond Meat's expanded McPlant offering approaching 'national launch', says BTIG 01/19/22 Goldman Sachs McDonald's price target raised to $287 from $284 at Goldman Sachs 01/14/22 Evercore ISI Evercore ups Texas Roadhouse to Outperform on underappreciated recovery leverage 01/06/22 UBS Texas Roadhouse upgraded to Buy from Neutral at UBS MCD McDonald's $254.64 / +1.52 (+0.60%) 10/27/21 McDonald's reports Q3 adjusted EPS $2.76, consensus $2.46 10/26/21 Notable companies reporting before tomorrow's open 07/28/21 McDonald's reports Q2 adjusted EPS $2.37, consensus $2.08 MCD McDonald's $254.64 / +1.52 (+0.60%) 01/20/22 McDonald's expanding test of Beyond Meat burger, CNBC reports 12/22/21 Publicis set to take McDonald's U.S. account from Omnicom, Ad Age reports 12/21/21 McDonald's Japan to ration fries amid supply chain crunch, FT reports 12/16/21 Former McDonald's CEO Easterbrook returns $105M to company, NY Times reports MCD McDonald's $254.64 / +1.52 (+0.60%) 01/05/22 Beyond's KFC, McDonald's launches not enough to turn some analysts bullish 01/04/22 Fly Intel: After-Hours Movers 01/03/22 Wall Street in Fives - Must Read Lists for Monday 01/03/22 Wall Street in Fives - Must Read Lists at Midday 01/27/22 McDonald's - MCD MCD McDonald's $254.64 / +1.52 (+0.60%) 10/27/21 Unusually active option classes on open October 27th 10/25/21 Unusually active option classes on open October 25th 10/14/21 Most profitable opening equity option purchase made in the prior session was 10/14/21 McDonald's call buyer realizes 16% same-day gains
Hot Stocks	Gilead says FDA grants expediated approval of Veklury sNDA » 18:25 01/21/22 01/21 18:25 01/21/22 18:25 GILD Gilead $68.50 / +0.68 (+1.00%) Gilead Sciences, Inc.… Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has granted expedited approval of a supplemental new drug application for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19. The expanded indication allows for Veklury to be administered in qualified outpatient settings that can administer daily intravenous infusions over three consecutive days. The FDA has also expanded the pediatric Emergency Use Authorization of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. These actions by the FDA come amidst a surge in COVID-19 cases and the reduced susceptibility to several anti-SARS-CoV-2 monoclonal antibodies due to the Omicron variant. In contrast, Veklury targets the highly conserved viral RNA polymerase, thereby retaining activity against existing SARS-CoV-2 variants of concern. In vitro laboratory testing shows that Veklury retains activity against the Omicron variant. To date, no major genetic changes have been identified in any of the known variants of concern that would significantly alter the viral RNA polymerase targeted by Veklury. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GILD Gilead $68.50 / +0.68 (+1.00%) 01/19/22 Sangamo CEO says preclinical studies moving forward 'beautifully' 01/10/22 Gilead in trial pact with Merck to evaluate Trodelvy -Keytruda combo in NSCLC 12/22/21 Gilead reports results from Phase 3 study of three-day course of Veklury 12/21/21 Gilead announces clinical hold on studies of injectable Lenacapavir in HIV GILD Gilead $68.50 / +0.68 (+1.00%) 01/06/22 Morgan Stanley Gilead downgraded to Equal Weight from Overweight at Morgan Stanley 12/22/21 Piper Sandler Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable' 12/22/21 Morgan Stanley Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley 12/15/21 Jefferies Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies GILD Gilead $68.50 / +0.68 (+1.00%) 10/28/21 Gilead raises FY21 adjusted EPS view to $7.90-$8.10 from $6.90-$7.25 10/28/21 Gilead Sciences reports Q3 adjusted EPS $2.65, consensus $1.74 10/28/21 Notable companies reporting after market close 07/29/21 Gilead raises FY21 adjusted EPS view to $6.90-$7.25 from $6.75-$7.45 GILD Gilead $68.50 / +0.68 (+1.00%) 01/18/22 Gilead alleges counterfeiting network illegally sold HIV drugs, WSJ reports 11/30/21 Moderna CEO expects current vaccines to struggle with omicron, FT says 11/29/21 Pfizer to ask FDA to authorize 'extra doses' for 16 and 17 year olds, WaPo says 08/26/21 Court overturns Gilead's $1.2B patent loss to Bristol-Myers, Bloomberg reports GILD Gilead $68.50 / +0.68 (+1.00%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung 11/18/21 Wall Street in Fives - Must Read Lists for Thursday 11/18/21 Wall Street in Fives - Must Read Lists at Midday 10/29/21 Wall Street in Fives - Must Read Lists for Friday 02/17/22 ASCO Genitourinary Cancers Symposium 2022 02/01/22 Gilead - GILD 02/28/22 PDUFA Date for Lenacapavir GILD Gilead $68.50 / +0.68 (+1.00%) 11/24/21 Gilead call volume above normal and directionally bullish 10/01/21 Gilead call volume above normal and directionally bullish 09/20/21 Gilead call volume above normal and directionally bullish 09/13/21 Gilead call volume above normal and directionally bullish
Recommendations	Zalando price target lowered to EUR 104 from EUR 110 at Barclays » 17:40 01/21/22 01/21 17:40 01/21/22 17:40 ZLNDY Zalando $37.55 / -0.81 (-2.11%) Barclays analyst Andrew… Barclays analyst Andrew Ross lowered the firm's price target on Zalando to EUR 104 from EUR 110 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research Periodicals ZLNDY Zalando $37.55 / -0.81 (-2.11%) 01/02/22 Fly Intel: Top five weekend stock stories ZLNDY Zalando $37.55 / -0.81 (-2.11%) 12/10/21 UBS Zalando price target lowered to EUR 101 from EUR 110 at UBS 11/05/21 Morgan Stanley Zalando price target lowered to EUR 92 from EUR 95 at Morgan Stanley 11/04/21 Barclays Zalando price target lowered to EUR 110 from EUR 113 at Barclays 11/04/21 Credit Suisse Zalando price target lowered to EUR 98 from EUR 106 at Credit Suisse ZLNDY Zalando $37.55 / -0.81 (-2.11%) 01/01/22 Zalando finds new customers in pandemic, Barron's says
Recommendations	UniCredit price target raised to EUR 15 from EUR 13.80 at Barclays » 17:39 01/21/22 01/21 17:39 01/21/22 17:39 UNCRY UniCredit $7.38 / -0.2 (-2.64%) Barclays analyst Paola… Barclays analyst Paola Sabbione raised the firm's price target on UniCredit to EUR 15 from EUR 13.80 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research Periodicals On The Fly UNCRY UniCredit $7.38 / -0.2 (-2.64%) 10/25/21 UniCredit, Italian MEF cease negotiations on Banca Monte dei Paschi acquisition UNCRY UniCredit $7.38 / -0.2 (-2.64%) 12/13/21 UBS UniCredit price target raised to EUR 19.50 from EUR 14.70 at UBS 12/13/21 Credit Suisse UniCredit price target raised to EUR 15.10 from EUR 13.80 at Credit Suisse 12/13/21 Citi UniCredit price target raised to EUR 15.70 from EUR 14.10 at Citi 12/10/21 Barclays UniCredit price target raised to EUR 13.80 from EUR 11.60 at Barclays UNCRY UniCredit $7.38 / -0.2 (-2.64%) 12/10/21 UniCredit to slash 950 jobs in Italy, Reuters reports 12/03/21 UniCredit's German arm to take large portion of layoffs, Reuters reports 12/01/21 UniCredit expects 3,000 job cuts as CEO seeks growth, Bloomberg says 07/29/21 UniCredit in talks to buy part of Monte Paschi, Bloomberg reports UNCRY UniCredit $7.38 / -0.2 (-2.64%) 12/01/21 Wall Street in Fives - Must Read Lists at Midday 07/29/21 Wall Street in Fives - Must Read Lists for Thursday

Recommendations	Trainline price target lowered to 245 GBp from 280 GBp at Barclays » 17:38 01/21/22 01/21 17:38 01/21/22 17:38 TNLIF Trainline $4.32 / + (+0.00%) Barclays analyst Andrew… Barclays analyst Andrew Ross lowered the firm's price target on Trainline to 245 GBp from 280 GBp and keeps an Underweight rating on the shares. ShowHide Related Items >><< Street Research TNLIF Trainline $4.32 / + (+0.00%) 12/09/21 JPMorgan Trainline price target lowered to 325 GBp from 358 GBp at JPMorgan 11/04/21 Barclays Trainline price target lowered to 280 GBp from 340 GBp at Barclays 11/04/21 JPMorgan Trainline price target lowered to 358 GBp from 399 GBp at JPMorgan 11/04/21 Morgan Stanley Trainline price target lowered to 380 GBp from 400 GBp at Morgan Stanley
Recommendations	South32 price target lowered to 175 GBp from 180 GBp at Barclays » 17:38 01/21/22 01/21 17:38 01/21/22 17:38 SOUHY South32 $14.69 / -0.55 (-3.61%) Barclays analyst Amos… Barclays analyst Amos Fletcher lowered the firm's price target on South32 to 175 GBp from 180 GBp and keeps an Underweight rating on the shares. ShowHide Related Items >><< Street Research SOUHY South32 $14.69 / -0.55 (-3.61%) 01/14/22 Barclays South32 price target lowered to 180 GBp from 200 GBp at Barclays 12/14/21 Investec South32 initiated with a Buy at Investec 11/26/21 BMO Capital South32 price target raised to 210 GBp from 200 GBp at BMO Capital 10/08/21 Barclays South32 price target raised to 200 GBp from 150 GBp at Barclays
Recommendations	Scout24 price target raised to EUR 70 from EUR 65.50 at Barclays » 17:37 01/21/22 01/21 17:37 01/21/22 17:37 SCOTF Scout24 $69.93 / + (+0.00%) Barclays analyst Andrew… Barclays analyst Andrew Ross raised the firm's price target on Scout24 to EUR 70 from EUR 65.50 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Street Research SCOTF Scout24 $69.93 / + (+0.00%) 01/20/22 Goldman Sachs Scout24 resumed with a Neutral at Goldman Sachs 01/14/22 JPMorgan Scout24 price target lowered to EUR 70 from EUR 71 at JPMorgan 12/13/21 Berenberg Scout24 initiated with a Buy at Berenberg 12/09/21 JPMorgan Scout24 upgraded to Overweight from Neutral at JPMorgan
Recommendations	Schibsted price target lowered to NOK 485 from NOK 565 at Barclays » 17:35 01/21/22 01/21 17:35 01/21/22 17:35 SBBTF Schibsted $37.04 / + (+0.00%) Barclays lowered the… Barclays lowered the firm's price target on Schibsted to NOK 485 from NOK 565 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research SBBTF Schibsted $37.04 / + (+0.00%) 01/21/22 Nordea Schibsted upgraded to Strong Buy from Buy at Nordea 01/20/22 JPMorgan Schibsted price target lowered to NOK 362 from NOK 438 at JPMorgan 12/10/21 Morgan Stanley Schibsted downgraded to Equal Weight from Overweight at Morgan Stanley 12/09/21 JPMorgan Schibsted downgraded to Neutral from Overweight at JPMorgan
Recommendations	Sandvik price target raised to SEK 255 from SEK 252 at Barclays » 17:34 01/21/22 01/21 17:34 01/21/22 17:34 SDVKY Sandvik $26.41 / -0.56 (-2.08%) Barclays analyst Lars… Barclays analyst Lars Brorson raised the firm's price target on Sandvik to SEK 255 from SEK 252 and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research SDVKY Sandvik $26.41 / -0.56 (-2.08%) 12/29/21 Sandvik acquires Dimensional Control Systems SDVKY Sandvik $26.41 / -0.56 (-2.08%) 01/21/22 Citi Sandvik price target raised to SEK 319 from SEK 314 at Citi 01/21/22 Morgan Stanley Sandvik price target raised to SEK 275 from SEK 269 at Morgan Stanley 01/14/22 Barclays Sandvik price target raised to SEK 252 from SEK 235 at Barclays 01/13/22 Morgan Stanley Sandvik price target raised to SEK 269 from SEK 265 at Morgan Stanley

Recommendations	Rio Tinto price target lowered to 4,400 GBp from 4,500 GBp at Barclays » 17:34 01/21/22 01/21 17:34 01/21/22 17:34 RIO Rio Tinto $74.36 / -1.795 (-2.36%) Barclays analyst Amos… Barclays analyst Amos Fletcher lowered the firm's price target on Rio Tinto to 4,400 GBp from 4,500 GBp and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Options RIO Rio Tinto $74.36 / -1.795 (-2.36%) 01/18/22 Pentwater Capital sends letter to Turquoise Hill board, urges action 01/13/22 Pentwater sends letter to Rio Tinto board calling for corporate governance moves 01/10/22 Rio Tinto orders Wabtec FLXdrive battery locomotives to cut emissions 01/10/22 Rio Tinto buys first battery-electric trains for Pilbara RIO Rio Tinto $74.36 / -1.795 (-2.36%) 01/20/22 Liberum Rio Tinto downgraded to Sell from Hold at Liberum 01/14/22 Barclays Rio Tinto price target raised to 4,500 GBp from 4,200 GBp at Barclays 01/13/22 JPMorgan Rio Tinto price target lowered to 4,840 GBp from 4,900 GBp at JPMorgan 01/07/22 Berenberg Rio Tinto upgraded to Buy after underperformance at Berenberg RIO Rio Tinto $74.36 / -1.795 (-2.36%) 12/23/21 Vale may buy stake in Anglo American iron ore mine in Brazil, Bloomberg says 09/18/21 Mining stocks offer cheap play on growth, Barron's says 07/27/21 U.K.'s FCA to probe Rio Tinto, $6.75B Mongolian mine, FT reports 07/25/21 Canadian union Unifor starts strike at Rio Tinto operations, Reuters says RIO Rio Tinto $74.36 / -1.795 (-2.36%) 10/14/21 Fly Intel: After-Hours Movers RIO Rio Tinto $74.36 / -1.795 (-2.36%) 01/12/22 Rio Tinto call volume above normal and directionally bullish 10/26/21 Largest borrow rate increases among liquid names 09/20/21 Unusually active option classes on open September 20th 09/16/21 Unusually active option classes on open September 16th
Recommendations	Rightmove price target raised to 630 GBp from 575 GBp at Barclays » 17:33 01/21/22 01/21 17:33 01/21/22 17:33 RTMVY Rightmove $18.01 / -0.19 (-1.04%) Barclays analyst Andrew… Barclays analyst Andrew Ross raised the firm's price target on Rightmove to 630 GBp from 575 GBp and keeps an Underweight rating on the shares. ShowHide Related Items >><< Street Research RTMVY Rightmove $18.01 / -0.19 (-1.04%) 01/20/22 Goldman Sachs Rightmove resumed with a Neutral at Goldman Sachs 10/19/21 JPMorgan Rightmove price target raised to 753 GBp from 724 GBp at JPMorgan 09/21/21 Citi Rightmove price target raised to 555 GBp from 450 GBp at Citi 09/15/21 Liberum Rightmove re-initiated with a Buy at Liberum
Recommendations	Richemont price target raised to CHF 165 from CHF 155 at Barclays » 17:33 01/21/22 01/21 17:33 01/21/22 17:33 CFRUY Richemont $14.52 / -0.64 (-4.22%) Barclays analyst Carole… Barclays analyst Carole Madjo raised the firm's price target on Richemont to CHF 165 from CHF 155 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research Periodicals Events CFRUY Richemont $14.52 / -0.64 (-4.22%) 01/20/22 UBS Richemont price target raised to CHF 184 from CHF 169 at UBS 01/18/22 Morgan Stanley Richemont price target raised to CHF 165 from CHF 152 at Morgan Stanley 01/04/22 Barclays Richemont price target raised to CHF 155 from CHF 150 at Barclays 12/21/21 Bryan Garnier Richemont upgraded to Buy from Neutral at Bryan Garnier CFRUY Richemont $14.52 / -0.64 (-4.22%) 11/12/21 Richemont in talks to cede control of Yoox Net-a-Porter, FT reports 05/20/22 Richemont - CFRUY
Recommendations	Prosus price target lowered to EUR 115.90 from EUR 121 at Barclays » 17:32 01/21/22 01/21 17:32 01/21/22 17:32 PROSY Prosus $17.32 / -0.08 (-0.46%) Barclays analyst Andrew… Barclays analyst Andrew Ross lowered the firm's price target on Prosus to EUR 115.90 from EUR 121 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research PROSY Prosus $17.32 / -0.08 (-0.46%) 08/31/21 Prosus to acquire BillDesk for $4.7B PROSY Prosus $17.32 / -0.08 (-0.46%) 01/20/22 Goldman Sachs Prosus resumed with a Buy at Goldman Sachs 01/10/22 Credit Suisse Prosus price target lowered to EUR 137 from EUR 140 at Credit Suisse 11/26/21 UBS Prosus price target raised to EUR 97 from EUR 89 at UBS 11/23/21 JPMorgan Prosus price target lowered to EUR 114 from EUR 135.90 at JPMorgan
Recommendations	Petra Diamonds price target lowered to 65 GBp from 70 GBp at Barclays » 17:31 01/21/22 01/21 17:31 01/21/22 17:31 PDLMF Petra Diamonds $1.10 / -0.14 (-11.29%) Barclays analyst Ian… Barclays analyst Ian Rossouw lowered the firm's price target on Petra Diamonds to 65 GBp from 70 GBp and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Street Research PDLMF Petra Diamonds $1.10 / -0.14 (-11.29%) 01/14/22 Barclays Petra Diamonds price target raised to 70 GBp from 1 GBp at Barclays 10/27/21 Panmure Gordon Petra Diamonds downgraded to Hold from Buy at Panmure Gordon

Recommendations	Persimmon price target lowered to 2,250 GBp from 2,500 GBp at Barclays » 17:31 01/21/22 01/21 17:31 01/21/22 17:31 PSMMY Persimmon $69.72 / -0.22 (-0.31%) Barclays analyst Gavin… Barclays analyst Gavin Jago lowered the firm's price target on Persimmon to 2,250 GBp from 2,500 GBp and keeps an Underweight rating on the shares. ShowHide Related Items >><< Street Research PSMMY Persimmon $69.72 / -0.22 (-0.31%) 01/21/22 UBS Persimmon price target lowered to 2,650 GBp from 3,015 GBp at UBS 01/20/22 Morgan Stanley Persimmon price target lowered to 2,900 GBp from 3,250 GBp at Morgan Stanley 01/14/22 JPMorgan Persimmon price target raised to 3,580 GBp from 3,530 GBp at JPMorgan 01/14/22 Deutsche Bank Persimmon downgraded to Hold from Buy at Deutsche Bank
Recommendations	Naspers price target lowered to ZAR 4,050 from ZAR 4,365 at Barclays » 17:30 01/21/22 01/21 17:30 01/21/22 17:30 NPSNY Naspers $33.65 / -0.67 (-1.95%) Barclays analyst Andrew… Barclays analyst Andrew Ross lowered the firm's price target on Naspers to ZAR 4,050 from ZAR 4,365 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research NPSNY Naspers $33.65 / -0.67 (-1.95%) 01/20/22 Goldman Sachs Naspers resumed with a Buy at Goldman Sachs 11/03/21 Barclays Naspers price target raised to ZAR 4,370 from ZAR 3,300 at Barclays 10/08/21 Barclays Naspers price target lowered to ZAR 3,300 from ZAR 3,945 at Barclays 10/04/21 Morgan Stanley Naspers resumed with an Overweight at Morgan Stanley
Recommendations	Moneysupermarket.com price target lowered to 260 GBp from 275 GBp at Barclays » 17:29 01/21/22 01/21 17:29 01/21/22 17:29 MYSRF Moneysupermarket.com $2.57 / + (+0.00%) Barclays analyst Andrew… Barclays analyst Andrew Ross lowered the firm's price target on Moneysupermarket.com to 260 GBp from 275 GBp and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research MYSRF Moneysupermarket.com $2.57 / + (+0.00%) 12/21/21 Citi Moneysupermarket.com upgraded to Buy from Neutral at Citi 11/01/21 Credit Suisse Moneysupermarket.com price target raised to 265 GBp at Credit Suisse 10/20/21 UBS Moneysupermarket.com price target lowered to 320 GBp from 345 GBp at UBS 10/20/21 Berenberg Moneysupermarket.com upgraded to Buy from Hold at Berenberg
Recommendations	Hochschild Mining price target lowered to 155 GBp from 160 GBp at Barclays » 17:29 01/21/22 01/21 17:29 01/21/22 17:29 HCHDF Hochschild Mining $1.62 / -0.12 (-6.90%) Barclays analyst Ian… Barclays analyst Ian Rossouw lowered the firm's price target on Hochschild Mining to 155 GBp from 160 GBp and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research HCHDF Hochschild Mining $1.62 / -0.12 (-6.90%) 11/22/21 Hochschild acknowledges alleged environmental complaints at Peru mines HCHDF Hochschild Mining $1.62 / -0.12 (-6.90%) 01/14/22 Barclays Hochschild Mining price target lowered to 160 GBp from 165 GBp at Barclays 12/13/21 JPMorgan Hochschild Mining upgraded to Overweight from Neutral at JPMorgan 11/25/21 BofA Hochschild Mining upgraded to Buy from Underperform at BofA 11/24/21 BofA Hochschild Mining downgraded to Underperform from Buy at BofA
Recommendations	HelloFresh price target lowered to EUR 110 from EUR 113 at Barclays » 17:28 01/21/22 01/21 17:28 01/21/22 17:28 HLFFF HelloFresh $65.00 / -2.4 (-3.56%) Barclays analyst Alvira… Barclays analyst Alvira Rao lowered the firm's price target on HelloFresh to EUR 110 from EUR 113 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research Earnings Periodicals HLFFF HelloFresh $65.00 / -2.4 (-3.56%) 01/14/22 JPMorgan HelloFresh price target lowered to EUR 68 from EUR 78 at JPMorgan 12/09/21 Barclays HelloFresh price target raised to EUR 113 from EUR 110 at Barclays 12/09/21 JPMorgan HelloFresh price target lowered to EUR 78 from EUR 85 at JPMorgan 12/03/21 Deutsche Bank HelloFresh price target raised to EUR 115 from EUR 107 at Deutsche Bank HLFFF HelloFresh $65.00 / -2.4 (-3.56%) 12/07/21 HelloFresh sees 2022 adjusted EBITDA EUR 500M-EUR 580M HLFFF HelloFresh $65.00 / -2.4 (-3.56%) 01/20/22 Citron Research goes long Blue Apron with $40 price target

Recommendations	Glencore price target raised to 470 GBp from 450 GBp at Barclays » 17:28 01/21/22 01/21 17:28 01/21/22 17:28 GLNCY Glencore $10.89 / -0.2 (-1.80%) Barclays analyst Ian… Barclays analyst Ian Rossouw raised the firm's price target on Glencore to 470 GBp from 450 GBp and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research Periodicals On The Fly GLNCY Glencore $10.89 / -0.2 (-1.80%) 11/15/21 Freyr, Glencore sign supply contract for up to 1,500 metric tons of cobalt 10/25/21 Cheniere and Glencore sign long-term LNG sale and purchase agreement 09/19/21 Fly Intel: Top five weekend stock stories GLNCY Glencore $10.89 / -0.2 (-1.80%) 01/19/22 Gordon Haskett Gordon Haskett notes Nutrien previously a target of BHP after Bloomberg report 01/14/22 Barclays Glencore price target raised to 450 GBp from 410 GBp at Barclays 01/13/22 JPMorgan Glencore price target lowered to ZAR 9,700 from ZAR 10,100 at JPMorgan 12/13/21 JPMorgan Glencore price target lowered to 470 GBp from 480 GBp at JPMorgan GLNCY Glencore $10.89 / -0.2 (-1.80%) 01/19/22 BHP eyes biggest rivals in hunt for 'transformational deal,' Bloomberg says 11/30/21 Activist Bluebell urges Glencore to spin off coal assets, FT reports 09/18/21 Mining stocks offer cheap play on growth, Barron's says 09/15/21 Teck Resources mulls possible coal business spinoff, Globe & Mail says GLNCY Glencore $10.89 / -0.2 (-1.80%) 11/30/21 Wall Street in Fives - Must Read Lists at Midday 09/16/21 Wall Street in Fives - Must Read Lists at Midday
Recommendations	Gem Diamonds price target lowered to 70 GBp from 75 GBp at Barclays » 17:27 01/21/22 01/21 17:27 01/21/22 17:27 GMDMF Gem Diamonds / + Barclays analyst Amos… Barclays analyst Amos Fletcher lowered the firm's price target on Gem Diamonds to 70 GBp from 75 GBp and keeps an Overweight rating on the shares. ShowHide Related Items >><< Street Research GMDMF Gem Diamonds / + 01/14/22 Barclays Gem Diamonds price target lowered to 75 GBp from 80 GBp at Barclays 10/07/21 Berenberg Gem Diamonds upgraded to Buy from Hold at Berenberg 07/08/21 Berenberg Gem Diamonds downgraded to Hold from Buy at Berenberg 04/07/21 Barclays Gem Diamonds price target raised to 80 GBp from 62 GBp at Barclays
Recommendations	Fresnillo price target lowered to 880 GBp from 900 GBp at Barclays » 17:27 01/21/22 01/21 17:27 01/21/22 17:27 FNLPF Fresnillo $11.23 / -0.37 (-3.19%) Barclays analyst Amos… Barclays analyst Amos Fletcher lowered the firm's price target on Fresnillo to 880 GBp from 900 GBp and keeps an Equal Weight rating on the shares. ShowHide Related Items >><< Company News Street Research FNLPF Fresnillo $11.23 / -0.37 (-3.19%) 12/27/21 MAG Silver, Fresnillo provide Juanicipio commissioning update FNLPF Fresnillo $11.23 / -0.37 (-3.19%) 12/13/21 JPMorgan Fresnillo price target raised to 950 GBp from 900 GBp at JPMorgan 11/30/21 RBC Capital Fresnillo price target lowered to 1,025 GBp from 1,075 GBp at RBC Capital 10/28/21 JPMorgan Fresnillo price target lowered to 900 GBp from 950 GBp at JPMorgan 10/18/21 UBS Fresnillo upgraded to Neutral from Sell at UBS
Syndicate	Aziyo Biologics files to sell 3.3M shares of Class A common stock for holders 17:24 01/21/22 01/21 17:24 01/21/22 17:24 AZYO Aziyo Biologics $6.09 / -0.24 (-3.79%) ShowHide Related Items >><< Company News Street Research Earnings Events AZYO Aziyo Biologics $6.09 / -0.24 (-3.79%) 01/10/22 Aziyo Biologics Inc (Class A Stock) trading resumes 01/10/22 Aziyo Biologics Inc (Class A Stock) trading halted, volatility trading pause 12/13/21 Aziyo Biologics Inc (Class A Stock) trading resumes 12/13/21 Aziyo Biologics Inc (Class A Stock) trading halted, volatility trading pause AZYO Aziyo Biologics $6.09 / -0.24 (-3.79%) 11/09/21 Piper Sandler Aziyo Biologics price target lowered to $11 from $14 at Piper Sandler 10/25/21 Piper Sandler Medtronic exit from Aziyo Biologics deal not unexpected, says Piper Sandler 06/10/21 Truist Aziyo Biologics price target lowered to $16 from $20 at Truist 06/07/21 Piper Sandler Piper cuts Aziyo target but sees Medtronic sticking with company AZYO Aziyo Biologics $6.09 / -0.24 (-3.79%) 11/09/21 Aziyo Biologics sees FY21 revenue $47M-$48M, consensus $48.72M 11/09/21 Aziyo Biologics reports Q3 EPS (81c), consensus (62c) 10/25/21 Aziyo Biologics reports preliminary Q3 revenue $11.5M, consensus $11.48M 01/29/22 58th Annual Meeting of STS
Recommendations	Ferrexpo price target lowered to 265 GBp from 280 GBp at Barclays » 17:24 01/21/22 01/21 17:24 01/21/22 17:24 FEEXF Ferrexpo $3.47 / -0.105 (-2.94%) Barclays analyst Kennedy… Barclays analyst Kennedy Nyangoni lowered the firm's price target on Ferrexpo to 265 GBp from 280 GBp and keeps an Underweight rating on the shares. ShowHide Related Items >><< Street Research FEEXF Ferrexpo $3.47 / -0.105 (-2.94%) 01/14/22 Barclays Ferrexpo price target raised to 280 GBp from 240 GBp at Barclays 12/13/21 JPMorgan Ferrexpo price target raised to 340 GBp from 280 GBp at JPMorgan 12/06/21 JPMorgan Ferrexpo price target lowered to 280 GBp from 370 GBp at JPMorgan 11/17/21 Credit Suisse Ferrexpo price target lowered to 350 GBp from 370 GBp at Credit Suisse

Events

Earnings calls, analyst events, roadshows and more

IBN
Today at 07:45

ICICI Bank - IBN Conference Calls
GSK ...
Tomorrow at 00:00

PDUFA Date for Cabotegravir Government Event
GOOGL ...
Tomorrow at 00:00

ALIS 2022 Conferences

JW Marriott at L.A., Los Angeles, CA
PFE ...
2022-01-24 at 00:00

PDUFA Date for Somatrogon - Extended Government Event
2022-01-24 at 00:00

Winter Restaurant, Foodservice, Gaming, Lodging & Leisure Virtual Summit Conferences

Virtual Summit
GOOGL ...
2022-01-24 at 00:00

ALIS 2022 Conferences

JW Marriott at L.A., Los Angeles, CA
2022-01-24 at 00:00

Citigroup Hosted Company Meetings at ALIS 2022 Conferences

Los Angeles, CA
WPRT
2022-01-24 at 00:00

Westport Firm Sponsored Meetings

Virtual Meeting
TPST
2022-01-24 at 00:00

Tempest Therapeutics Firm Sponsored Meetings

Virtual Meeting
VOR
2022-01-24 at 00:00

Vor Biopharma Firm Sponsored Meetings

Virtual Meeting

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	PWP X PWP Perella Weinberg Partners Spot Secondary Managers: JMP Securities Priced at: $10.75 3.502M Shares SBNY X SBNY Signature Bank Spot Secondary Managers: Goldman Sachs, Morgan Stanley & Jefferies Priced at: $352.00 2.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	STRR X STRR Star Equity Secondary Managers: Maxim Priced at: $1.50 9.5M Shares AMH X AMH American Homes 4 Rents Spot Secondary Managers: BofA, Citi, JPMorgan & Morgan Stanley Priced at: $39.15 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVA X EVA Enviva Partners Spot Secondary Managers: Goldman Sachs, JPMorgan, Citi, Barclays, BMO Capital, HSBC, RBC Capital & Truist, Loop Capital, Raymond James, US Capital Advisors Priced at: $70.00 4.3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	JUNS X JUNS Jupiter Neurosciences IPO Managers: Roth Capital & Desjardins $5.00-7.00 3.333M Shares
Tues	No deals
Wed	FSPR X FSPR Four Springs Capital IPO Managers: Morgan Stanley, Goldman Sachs & Wells Fargo, Mizuho, Scotiabank, Nomura, Berenberg $13.00-15.00 18M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RHDM X RHDM Rhodium Enterprises IPO Managers: B. Riley & Cowen, Needham, DA Davidson, Northland $12.00-14.00 7.692M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	SMSA X SMSA Samsara Vision IPO Managers: ThinkEquity $5.00-7.00 28.75M Shares
Fri	No deals

View All Syndicate Announcements »

Digital World reports receipt of 'fact-finding inquiries' from regulators

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access